Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of diagnostic and prognostic ultrasound imaging biomarkers for plantar heel pain

Award Number: R33AT012275
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/17/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Development of diagnostic and prognostic ultrasound imaging biomarkers for plantar heel pain - Project Summary/Abstract Myofascial pain remains an underdiagnosed contributor to a range of musculoskeletal pain conditions. The lack of validated biomarkers limits the ability to objectively detect myofascial pain, probe underlying pain mechanisms, and guide targeted treatments. This proposal will address this gap by quantifying the biochemical, biomechanical, and structural properties of myofascial pain using advanced, quantitative imaging techniques. As a model of myofascial pain, we have chosen plantar fasciitis, which affects 1 out of every 10 adults. Our long-term goal is to enhance musculoskeletal pain management by creating better tools for detecting abnormal myofascial tissue that enable more individualized treatment. The objective of the R61 phase is to use novel imaging techniques to develop a diagnostic biosignature to objectively and accurately determine the location and severity of abnormal myofascial tissue. Our approach will use a cross-sectional study design with 3 groups: plantar fasciitis (n=50), Achilles tendinopathy (n=25), and pain-free controls (n=25) to test Specific Aim 1: Develop a diagnostic imaging biosignature of myofascial tissue to differentiate individuals with plantar fasciitis from other foot pain without a myofascial component (Achilles tendinopathy) and from matched pain-free controls. The objective of the R33 phase is to use novel imaging techniques to develop a predictive biosignature to identify individuals most likely to respond to DN, and a response biosignature to guide dosing or continued use of DN for myofascial pain for individuals with plantar foot pain. Our approach will use a parallel-group, doubleblinded randomized controlled trial (RCT) design with imaging measured before, during (1 m.), and after treatment (3 & 6 m.). Participants will be randomized to one of two groups: 1) DN + standard care, or 2) Sham DN + standard care to test Specific Aim 2: Determine 2A) predictive (Independent variable: imaging biosignature; Primary outcome: Pain Intensity) and 2B) response (Independent variable: DN vs. Sham DN; Primary outcome: Imaging biosignature/biomarkers) imaging biosignatures in an RCT. Exploratory Aim 3: Will develop composite biosignatures, that combine multiple imaging biomarkers developed in Aims 1 or 2 with psychosocial factors, to enhance the diagnostic, predictive, or response capability for myofascial pain. Transition criteria. 1) Adequate recruitment with >90% of participants in each group enrolled; 2) Adequate representation with neither sex exceeding 60% of the sample; 3) Minimal missing data (<5%) for collected outcomes; 4) At least 2 diagnostic imaging biomarkers with an ROC AUC > 0.7 and FDRs < 0.1; 5-8) Submit DSMP, Study Accrual and Retention Plan, Final sample size and statistical analysis informed by mock recruitment, and R33 transition application, including implementation of an effective sham DN.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $3,027,765 )
2026	2026	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	The National Institute of Neurological Disorders and Stroke (NINDS) Helping to End Addiction Long-term® (HEAL) Initiative	000	2	9/16/2026	SUPPLEMENT FOR EXPANSION	$3,027,765
														Subtotal = $3,027,765

Grand Total All Awards = $3,027,765

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of diagnostic and prognostic ultrasound imaging biomarkers for plantar heel pain

Award Number: R33AT012275

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/17/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer